T. Gräslund

发表

Selection and characterization of Affibody® ligands to the transcription factor c‐Jun

E. Lundberg, H. Brismar, T. Gräslund, 2009, Biotechnology and applied biochemistry.

Incorporation of a Hydrophilic Spacer Reduces Hepatic Uptake of HER2-Targeting Affibody–DM1 Drug Conjugates

V. Tolmachev, A. Orlova, Mohamed Altai, 2019, Cancers.

Robust Expression of the Human Neonatal Fc Receptor in a Truncated Soluble Form and as a Full-Length Membrane-Bound Protein in Fusion with eGFP

M. Uhlén, J. Löfblom, T. Gräslund, 2013, PloS one.

Influence of the Position and Composition of Radiometals and Radioiodine Labels on Imaging of Epcam Expression in Prostate Cancer Model Using the DARPin Ec1

A. Schulga, V. Tolmachev, A. Orlova, 2021, Cancers.

Identification of four novel T cell autoantigens and personal autoreactive profiles in multiple sclerosis

H. Tegel, T. Olsson, I. Kockum, 2022, Science advances.

Exploring Strategies for the Design of Artificial Transcription Factors

C. Barbas, T. Gräslund, L. Magnenat, 2005, Journal of Biological Chemistry.

Potent and specific fusion toxins consisting of a HER2‑binding, ABD‑derived affinity protein, fused to truncated versions of Pseudomonas exotoxin A.

S. Hober, V. Tolmachev, A. Orlova, 2019, International journal of oncology.

Preclinical Evaluation of a New Format of 68Ga- and 111In-Labeled Affibody Molecule ZIGF-1R:4551 for the Visualization of IGF-1R Expression in Malignant Tumors Using PET and SPECT

V. Tolmachev, A. Orlova, T. Gräslund, 2022, Pharmaceutics.

Effect of a radiolabel biochemical nature on tumor-targeting properties of EpCAM-binding engineered scaffold protein DARPin Ec1.

A. Schulga, V. Tolmachev, A. Orlova, 2019, International journal of biological macromolecules.

Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart

S. Hober, V. Tolmachev, A. Orlova, 2022, Pharmaceutics.

Protein Engineering Strategies for Selective Protein Purification

Torbjörn Gräslund, Sophia Hober, M. Hedhammar, 2005 .

Proof-of-Concept of Continuous Transfection for Adeno-Associated Virus Production in Microcarrier-Based Culture

T. Gräslund, Véronique Chotteau, B. Ladd, 2022, Processes.

An in vivo half-life extended prolactin receptor antagonist can prevent STAT5 phosphorylation

G. Norstedt, T. Gräslund, Amira Alkharusi, 2019, PloS one.

Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.

E. Lundberg, E. Vernet, P. Nygren, 2008, Journal of immunological methods.

Targeting Tumor Cells Overexpressing the Human Epidermal Growth Factor Receptor 3 with Potent Drug Conjugates Based on Affibody Molecules

S. Ståhl, J. Löfblom, A. Orlova, 2022, Biomedicines.

Production of a thermostable DNA polymerase by site-specific cleavage of a heat-eluted affinity fusion protein.

M. Uhlén, P. Nygren, J. Nilsson, 1997, Protein expression and purification.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

L. Abrahmsén, V. Tolmachev, A. Orlova, 2012, The Journal of Nuclear Medicine.

Evaluation of 99mTc-ZIGF1R:4551-GGGC affibody molecule, a new probe for imaging of insulin-like growth factor type 1 receptor expression

V. Tolmachev, A. Orlova, Mohamed Altai, 2014, Amino Acids.

Integrated strategy for selective expanded bed ion-exchange adsorption and site-specific protein processing using gene fusion technology.

Torbjörn Gräslund, Sophia Hober, Mathias Uhlén, 2002, Journal of biotechnology.

Novel antigen design for the generation of antibodies to G-protein-coupled receptors.

T. Hökfelt, C. Lindskog, P. Angelidou, 2011, Journal of immunological methods.

A novel method for reproducible fluorescent labeling of small amounts of antibodies on solid phase.

Torbjörn Gräslund, Emma Lundberg, Mathias Uhlén, 2007, Journal of immunological methods.

S100A4 interacts with p53 in the nucleus and promotes p53 degradation

B. Zhivotovsky, E. Vernet, J. Lehtiö, 2013, Oncogene.

Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model

A. Schulga, V. Tolmachev, A. Orlova, 2021, Cancers.

Affibody Molecules in Biotechnological and Medical Applications.

Stefan Ståhl, Torbjörn Gräslund, Amelie Eriksson Karlström, 2017, Trends in biotechnology.

Inhibitory effects of H-Ras/Raf-1-binding affibody molecules on synovial cell function

P. Nygren, S. Shibasaki, T. Gräslund, 2014, AMB Express.

Negatively charged purification tags for selective anion-exchange recovery.

M. Uhlén, M. Hedhammar, S. Hober, 2004, Protein engineering, design & selection : PEDS.

Affibody-mediated retention of the epidermal growth factor receptor in the secretory compartments leads to inhibition of phosphorylation in the kinase domain.

E. Lundberg, E. Vernet, P. Nygren, 2009, New biotechnology.

Stimulation of prolactin receptor induces STAT-5 phosphorylation and cellular invasion in glioblastoma multiforme

G. Norstedt, F. Zadjali, T. Gräslund, 2016, Oncotarget.

AB0134 Affibody Molecules Inhibiting the Interaction between RAS and RAF Suppress the Proliferation and the Production of Inflammatory Mediators by Synovial Cells

S. Shibasaki, T. Gräslund, H. Sano, 2014 .

Fusion of the mouse IgG1 Fc domain to the VHH fragment (ARP1) enhances protection in a mouse model of rotavirus

L. Hammarström, H. Marcotte, T. Gräslund, 2016, Scientific Reports.

Affibody-Derived Drug Conjugates Targeting HER2: Effect of Drug Load on Cytotoxicity and Biodistribution

V. Tolmachev, A. Orlova, T. Gräslund, 2021, Pharmaceutics.

Drug Conjugates Based on a Monovalent Affibody Targeting Vector Can Efficiently Eradicate HER2 Positive Human Tumors in an Experimental Mouse Model

V. Tolmachev, A. Orlova, T. Gräslund, 2020, Cancers.

Display of active subtilisin 309 on phage: analysis of parameters influencing the selection of subtilisin variants with changed substrate specificity from libraries using phosphonylating inhibitors.

J Fastrez, T. Borchert, J. Fastrez, 2000, Journal of molecular biology.

Evolution of programmable zinc finger-recombinases with activity in human cells.

Torbjörn Gräslund, Russell M Gordley, Russell M. Gordley, 2007, Journal of molecular biology.

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein

Fredrik Y Frejd, M. Uhlén, L. Abrahmsén, 2014, Proceedings of the National Academy of Sciences.

Improving the tolerance of a protein a analogue to repeated alkaline exposures using a bypass mutagenesis approach

Torbjörn Gräslund, Sophia Hober, Anna Sjöberg, 2004, Proteins.

Charge engineering of a protein domain to allow efficient ion-exchange recovery.

S. Hober, M. Uhlén, P. Nygren, 2000, Protein engineering.

Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain.

Fredrik Y Frejd, V. Tolmachev, F. Frejd, 2015, International journal of oncology.

In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor

I. Höidén-Guthenberg, F. Frejd, T. Gräslund, 2018, Scientific Reports.

HAHAHA-, HIHIHI-. HKHKHK. HHHHHH- and HEHEHE- tags : Influence of position and composition of histidine-containing tags on biodistribution of [99mTc(CO) 3]+- labeled affibody molecules

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2013 .

HAHAHA, HEHEHE, HIHIHI, or HKHKHK: influence of position and composition of histidine containing tags on biodistribution of [(99m)Tc(CO)3](+)-labeled affibody molecules.

S. Hosseinimehr, V. Tolmachev, A. Orlova, 2013, Journal of medicinal chemistry.

Evaluation of a HER2-targeting affibody molecule combining an N-terminal HEHEHE-tag with a GGGC chelator for 99mTc-labelling at the C terminus

S. Ståhl, V. Tolmachev, A. Orlova, 2012, Tumor Biology.

HEHEHE-tagged affibody molecule may be purified by IMAC, is conveniently labeled with [⁹⁹(m)Tc(CO)₃](+), and shows improved biodistribution with reduced hepatic radioactivity accumulation.

L. Abrahmsén, S. Hosseinimehr, V. Tolmachev, 2010, Bioconjugate chemistry.

Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with 99mTc for Radionuclide Imaging of HER2 Expression in Cancer

A. Schulga, V. Tolmachev, S. Deyev, 2022, International journal of molecular sciences.

Influence of molecular design on biodistribution and targeting properties of an Affibody-fused HER2-recognising anticancer toxin.

V. Tolmachev, A. Orlova, Mohamed Altai, 2016, International journal of oncology.

In vitro selection of enzymatically active lipase variants from phage libraries using a mechanism-based inhibitor.

T. Borchert, P. Nygren, H. Deussen, 2001, Gene.

Harnessing secretory pathway differences between HEK293 and CHO to rescue production of difficult to express proteins

F. Edfors, N. Lewis, Johan Rockberg, 2021, bioRxiv.

Effect of Inter-Domain Linker Composition on Biodistribution of ABD-Fused Affibody-Drug Conjugates Targeting HER2

V. Tolmachev, A. Orlova, T. Gräslund, 2022, Pharmaceutics.

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours

V. Tolmachev, A. Orlova, K. Andersson, 2013, European Journal of Nuclear Medicine and Molecular Imaging.

Comparison of HER2-targeted affibody conjugates loaded with auristatin- and maytansine-derived drugs.

V. Tolmachev, A. Orlova, T. Gräslund, 2023, Journal of controlled release : official journal of the Controlled Release Society.

Targeting HER2 Expressing Tumors with a Potent Drug Conjugate Based on an Albumin Binding Domain-Derived Affinity Protein

S. Hober, V. Tolmachev, A. Orlova, 2021, Pharmaceutics.

The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy

V. Tolmachev, A. Orlova, Mohamed Altai, 2021, Pharmaceutics.

Strategy for highly selective ion-exchange capture using a charge-polarizing fusion partner.

Torbjörn Gräslund, Sophia Hober, Mathias Uhlén, 2002, Journal of chromatography. A.

Affibody‐derived drug conjugates: Potent cytotoxic molecules for treatment of HER2 over‐expressing tumors

V. Tolmachev, A. Orlova, Mohamed Altai, 2018, Journal of controlled release : official journal of the Controlled Release Society.

Imaging of Insulinlike Growth Factor Type 1 Receptor in Prostate Cancer Xenografts Using the Affibody Molecule 111In-DOTA-ZIGF1R:4551

L. Abrahmsén, V. Tolmachev, A. Orlova, 2012, The Journal of Nuclear Medicine.

Affinity-based entrapment of the HER2 receptor in the endoplasmic reticulum using an affibody molecule.

E. Lundberg, E. Vernet, P. Nygren, 2008, Journal of immunological methods.

Site-specifically conjugated anti-HER2 Affibody molecules as one-step reagents for target expression analyses on cells and xenograft samples.

E. Lundberg, M. Uhlén, I. Höidén-Guthenberg, 2007, Journal of immunological methods.

HER2-Specific Pseudomonas Exotoxin A PE25 Based Fusions: Influence of Targeting Domain on Target Binding, Toxicity, and In Vivo Biodistribution

S. Hober, V. Tolmachev, A. Orlova, 2020, Pharmaceutics.

Affibody Molecules in Biotechnological and Medical Applications.

Fredrik Y Frejd, P. Nygren, S. Ståhl, 2017, Trends in biotechnology.

Selection of affibody molecules to the ligand‐binding site of the insulin‐like growth factor‐1 receptor

E. Lundberg, E. Vernet, I. Höidén-Guthenberg, 2010, Biotechnology and applied biochemistry.

Nanoparticles targeting the intestinal Fc receptor enhance intestinal cellular trafficking of semaglutide.

T. Gräslund, Soraia Pinto, J. Garousi, 2024, Journal of controlled release : official journal of the Controlled Release Society.

Selection and characterisation of affibody molecules inhibiting the interaction between Ras and Raf in vitro.

E. Lundberg, Marie Skogs, E. Vernet, 2010, New biotechnology.

Half-life extension via ADB-fusion leads to higher tumor uptake of an affibody-drug conjugate compared to PAS- and XTENylation.

A. Orlova, T. Gräslund, A. Vorobyeva, 2024, Journal of controlled release : official journal of the Controlled Release Society.

An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein

M. Uhlén, L. Abrahmsén, C. Ekblad, 2014, Proceedings of the National Academy of Sciences.